Epidarex Capital
Venture capitalBethesda · Pre-Seed–Series A
Investment thesis
Epidarex identifies and funds seed and Series A life science companies from emerging research hubs in the US and UK, focusing on disruptive platform technologies addressing unmet medical needs. The firm prioritizes novel innovations with sustainable competitive advantages, robust intellectual property, clear regulatory strategies, and strong evidence of market validation. Investment decisions emphasize founders with exceptional drive, efficient capital use, and the dual potential for outstanding financial returns and meaningful patient impact.
Source: firm website, verified Jul 21, 2026.
What they invest in
from 19 of 54 portfolio companiesBiotech ×17Medical Devices ×15Healthtech ×6AI & Machine Learning ×4Digital Health ×3Deep Tech ×2Longevity ×1
HQs:United States×3United Kingdom×1
Investments · 54 tracked
founders shown can be your intro pathLUNAC Therapeutics develops first-in-class oral and intravenous anticoagulants targeting activated Factor XII to treat and prevent thrombotic events with reduced bleeding risk. The company focuses on cardiovascular and blood coagulation therapies for patients requiring anticoagulation.
BiotechHealthtechMedical DevicesLeeds, GB
Professor Helen Philippou(Scientific Founder)Dr. Richard Foster(Scientific Founder)
Developing new modulators of the adenosine pathway for cancer treatment.
NASDAQ-listed company developing therapies for complement cascade-driven diseases in haematology, ophthalmology, and nephrology.
Developing novel therapeutics targeting free fatty acid receptors for metabolic diseases, including NASH.
University of Glasgow spin-out with pioneering CellOPTIQ technology to evaluate cardiotoxicity risk in pharmaceuticals.
Technology-focused company on rational drug design for cancer and chronic inflammatory diseases (acquired by Aclaris Therapeutics in August 2017).
University of Southampton spin-out deploying MicrocycleTM platform to build first-in-class therapeutics targeting protein-protein interactions.
Developing next-generation small molecule therapeutics based on differentiated protein degradation technology.
University of Edinburgh spin-out clinical-phase biotech developing C-Met molecular targeting technology for cancer radiotherapy and imaging.
Clinical stage company developing novel therapies for respiratory diseases through ion channel modulation.
King's College London spin-out clinical stage company developing IgE-based antibody therapeutics for cancer treatment.
RNA-targeted company focused on upregulating new targets to transform treatment of neurodegenerative diseases.
University of Maryland spin-out commercializing minimally invasive image-guided surgical tool for beating heart mitral valve repair (acquired by Edwards Lifesciences in December 2017).
Emory University spin-out developing novel nucleic acid-based targeted delivery platform for cancer therapeutics.
University of Edinburgh spin-out immunemetabolic company with expertise in the kynurenine pathway and KMO biology.
Preclinical-stage drug discovery company co-founded by Epidarex-Exeed and Axxam developing first-in-class precision medicines for epileptic and neurological disorders.
King's College London spin-out focused on developing new cancer treatments using engineered T cells.
US biotech developing novel therapeutics for neurodegenerative diseases by normalizing intracellular trafficking and autophagy.
University of Leeds spin-out developing next generation oral anticoagulants for treatment and prevention of thrombotic events.
University of Edinburgh spin-out early-stage immuno-oncology company developing next-generation macrophage-modulating therapies.
Developing proprietary drug candidates targeting phosphodiesterase 4 enzymes for chronic inflammatory and degenerative kidney diseases.
Therapeutic company developing Ruvonoflast for treating inflammation and cardiometabolic conditions
Emory University spinout developing novel transcatheter mitral valve repair technology for functional mitral regurgitation.
Medical technology company developing next-generation stroke aspiration technology
Medical device company developing novel aspiration system to treat ischemic stroke.
Device company developing novel catheter-based treatment for COPD.
University of Aberdeen spin-out developing nano-synthetic bone graft substitutes using advanced nanostructures for bone repair (acquired November 2020).
University of Virginia spin-out developing next generation IL-2 therapies to restore natural immunological response in various diseases.
UK biotech creating advancement in oncolytic viral therapy using patient-centric phenotypic screening platform.
Clinical stage therapeutics company using nanoparticle technology to target autoimmune and inflammatory diseases via antigen-specific immune tolerance.
Lario Therapeutics develops first-in-class precision medicines for severe neurological disorders, including epileptic encephalopathies and Parkinson's disease. The company targets disease-modifying treatments based on genetically validated targets.
BiotechDigital Health
NodThera develops clinical-stage molecular therapies for cardiometabolic and neuroinflammatory diseases. The company focuses on inflammation-based treatments targeting cardiovascular disease, metabolic dysfunction, and neuroinflammation affecting large patient populations.
BiotechHealthtechMedical Devices
Clyde Biosciences provides a human iPSC-derived cardiomyocyte platform called CellOPTIQ® that enables earlier detection of cardiovascular risk and cardiotoxicity assessment for pharmaceutical and biotech companies during drug development.
BiotechHealthtechMedical Devices
Curve Therapeutics develops cyclic peptide and small molecule drugs using its Microcycle discovery platform to target intracellular disease mechanisms. The company focuses on oncology, immunology, and inflammation treatments.
AI & Machine LearningBiotechDeep Tech
Enterprise Therapeutics develops novel drug therapies targeting the underlying mechanisms of mucus congestion in respiratory diseases including cystic fibrosis, asthma, and COPD. The company aims to reduce lung infection frequency and improve patient quality of life through disease-modifying treatments.
BiotechHealthtechMedical Devices
Harness Therapeutics develops precision therapies for neurodegenerative diseases including Huntington's, Parkinson's, Alzheimer's, and ALS through its proprietary protein modulation platform. The company targets disease modification in hard-to-treat CNS conditions using RNA biology and novel therapeutic approaches.
AI & Machine LearningBiotechMedical Devices
Kodikaz develops Zip-Code, a non-viral cell-specific delivery platform for gene therapy applications, particularly focused on oncology and cancer treatments. The company serves oncologists and patients with cancer seeking advanced therapeutic solutions.
AI & Machine LearningBiotechMedical DevicesAtlanta, US
Anthony Johnson(Co-Founder & CEO)Dr. Leon Bernal-Mizrachi(Co-Founder, CSO)
Leucid Bio develops a proprietary Lateral CAR platform for chimeric antigen receptor T-cell (CAR-T) therapies in oncology. The platform is designed to enhance T-cell potency and reduce toxicity compared to previous-generation CAR-T treatments.
AI & Machine LearningBiotechMedical Devices
John Maher
Libra Therapeutics develops small molecule therapeutics targeting lysosomal function and autophagy to treat neurodegenerative diseases including ALS, Parkinson's, Alzheimer's, and Huntington's disease. The company's approach aims to restore cellular balance by enhancing the body's natural ability to clear toxic proteins and dysfunctional organelles.
BiotechLongevityMedical Devices
Dr. Gill(Chief Scientific Officer)
Macomics develops novel drug treatments that target macrophage activity to address diseases with limited existing therapeutics. The company focuses on macrophage biology and drug discovery for therapeutic applications.
Biotech
Mironid develops drug therapies targeting cAMP degrading phosphodiesterase enzymes for autosomal dominant polycystic kidney disease and other rare kidney diseases with significant unmet medical needs.
BiotechHealthtechMedical Devices
Adele Rowley(Chief Scientific Officer)
Nyra Medical develops the CARLEN System, a transcatheter device for single-leaflet repair of functional mitral regurgitation that preserves native valve function. The company serves patients with mitral valve disease, including those who are unsuitable for existing treatment options.
Digital HealthMedical DevicesAtlanta, US
Dr. Murali Padala(Founder)Dr. Eric Sarin(Founder)Dr. Kirthana Suresh(Founder)Lori Chmura(CEO)
Medical Devices
Ryme Medical develops a catheter-based therapy to treat chronic obstructive pulmonary disease (COPD) by reducing airway inflammation and improving patient outcomes. The company targets patients with COPD who are inadequately managed by existing medications and pulmonary rehabilitation.
BiotechHealthtechMedical DevicesMountain View, US
Slate Bio develops regulatory T cell (Treg) therapies for treating autoimmune diseases. The company focuses on advancing immunology treatments for patients with autoimmune conditions.
BiotechDigital HealthMedical Devices
Theolytics develops oncolytic adenovirus-based immunotherapies to overcome the tumor microenvironment barriers in solid cancers. The company uses its Adenovo platform to identify and advance therapeutic candidates designed to target cancer cells and supporting tissue while enabling immune activation.
BiotechDeep TechMedical Devices
Topas Therapeutics develops a nanoparticle platform technology to establish immune tolerance in autoimmune and immune-mediated diseases. The company's lead candidate, TPM502, targets liver cells to drive anti-inflammatory immune responses and is in Phase 2b clinical trials for celiac disease.
BiotechMedical Devices
Epsilogen discovers and develops antibody therapeutics across multiple immunoglobulin isotypes (IgE, IgA, IgG) for cancer treatment. The company's lead candidate, MOv18 IgE, is the first therapeutic IgE antibody in clinical development, currently in phase Ib trials for platinum-resistant ovarian cancer.
Biotech
Frequently asked questions
- What stage does Epidarex Capital invest at?
- Epidarex Capital invests at the Pre-Seed, Seed, Series A stages.
- What sectors does Epidarex Capital focus on?
- Epidarex Capital focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Epidarex Capital located?
- Epidarex Capital is headquartered in Bethesda, US.
- Does Epidarex Capital lead rounds?
- Yes, Epidarex Capital leads investment rounds.
Similar investors
B Capital is a venture capital firm managing over $12 billion in assets with a stage-based fund approach. The firm invests across early to late-stage companies in technology, healthcare, and energy & resilience sectors, with 200+ portfolio companies and 9 global offices.
Breyer Capital is a venture capital firm that invests in high-impact entrepreneurs with a strategic focus on companies leveraging artificial intelligence and machine learning to transform technology sectors globally.
DCVC is a deep tech venture capital firm with over a dozen years of experience backing entrepreneurs using computational approaches to solve trillion-dollar problems across industries including AI, climate, materials science, robotics, space, and biology.
Innovestor is a Finnish investment manager that operates across venture capital, real estate, and energy storage sectors. The firm invests in early-stage technology and life science startups, energy-efficient commercial real estate, and battery storage and solar solutions. Innovestor also provides corporate venturing advisory services.
An early-stage venture capital firm investing in technology founders building solutions across multiple sectors.